Activity of oxaliplatin against human tumor colony-forming units

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 1021-1029

  Raymond, Eric ^a,b   Lawrence, Richard ^b   Izbicka, Elzbieta ^b   Faivre, Sandrine ^b   Von Hoff, Daniel D ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CTRC Institute for Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PACLITAXEL;

ARTICLE; CANCER INHIBITION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG RESISTANCE; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TUMOR;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0031895783     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Chaney, S. The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand (Review). Int. J. Oncol., 6: 1291-1305, 1995.
2. Kidani, Y., Inagaki, K., and Tsugagoshi, S. Examination of antitumor activities of platinum complexes of 1,2-diaminocyclohexane isomers. Gann, 67: 921-922, 1976.
3. Kidani, Y., Inagaki, K., Ligo, M., Hoshi, A., and Kuretani, K. Antitumor activity of 1,2-diaminocyclohexane-platinum complexes against sarcoma-180 ascite form. J. Med. Chem., 21: 1315-1318, 1978.
4. Siddik, Z. H., al-Baker, S., Thai, G., and Khokhar, A. R. Antitumor activity of isomeric 1,2-diaminocyclohexane platinum(IV) complexes. J. Cancer Res. Clin. Oncol., 120: 409-414, 1994.
5. Skou, G., Mangold, G., Dexter, D., and Von Hoff, D. Comparison of an oxaliplatin-Taxol versus a carboplatin-Taxol regimen in the treatment of the MV-522 human lung tumor xenografts. Proc. Am. Assoc. Cancer Res., 37: 375, 1996.
6. Raymond, E., Buquet-Fagot, Djelloul, C., J., Mester, E., Cvitkovic, C., Louvet, C., and Gespach, C. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidase synthase inhibitor AG337 in human colon, breast, and ovarian cancers. Anticancer Drugs, 8: 876-885, 1997.
7. Bastian, G. Report on the pharmacokinetic of oxaliplatin in patients with normal and impaired renal function. Ann. Oncol., 5: 126, 1994.
8. Extra, J. M., Espie, M., Calvo, F., Ferme, C., Mignot, L., and Marty, M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother. Pharmacol., 25: 299-303, 1990.
9. Schmidt, W., and Chaney, S. G. Role of carrier ligand in platinum resistance of human carcinoma cell lines. Cancer Res., 53: 799-805, 1993.
10. Petersen, L. N., Mamenta, E. L., Stevnsner, T., Chaney, S. G., and Bohr, V. A. Increased gene specific repair of cisplatin induced inter-strand crosslinks in cisplatin resistant cell lines, and studies on carrier ligand specificity. Carcinogenesis (Lond.), 17: 2597-2602, 1996.
11. Mamenta, E. L., Poma, E. E., Kaufmann, W. K., Delmastro, D. A., Grady, H. L., and Chaney, S. G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Res., 54: 3500-3505, 1994.
12. Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K., and Fojo, T. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol., 52: 1855-1865, 1996.
13. Page, J. D., Husain, I., Sancar, A., and Chaney, S. G. Effects of the diaminocyclohexane carrier ligand on platinum adduct formation, repair, and lethality. Biochemistry, 29: 1016-1024, 1990.
14. Bruk, M. A., Bau, R., Noji, M., Inagaki, K., and Kidani, Y. The crystal structure and absolute configurations of the antitumor complexes Pt(oxalato)(1R,2R-cyclohexanediamine) and Pt(malanato)(1R,2R-cyclohexanediamine). Inorg. Chem. Acta, 92: 279-284, 1984.
15. Lock, C. J. L., and Pilon, P. Tris-[cis-dichloro(1,2-diaminocyclohexane)platinum(II)] hydrate and cis-dibromo(1,2-diaminocyclohexane)platinum(II). Acta Crystallogr. Sect. B Struct. Sci., B27: 45-49, 1981.
16. Fink, D., Nebel, S., Aebi, S., Zheng, H., Cenni, B., Nehme, A., Christen, R. D., and Howell, S. B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res., 56: 4881-4886, 1996.
17. Gamelin, E., Le Bouil, A., Boisdron-Celle, M., Turcant, A., Delva, R., Cailleux, A., Krikorian, A., Brienza, S., Cvitkovic, E., Robert, J., Larra, F., and Allain, P. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluorouracil in colorectal cancer patients. Clin. Cancer Res., 3: 891-899, 1997.
18. Pendyala, L., and Creaven, P. J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res., 53: 5970-5976, 1993.
19. Pendyala, L., Kidani, Y., Perez, R., Wilkes, J., Bernacki, R. J., and Creaven, P. J. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Lett., 97: 177-184, 1995.
20. Bleiberg, H. Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin. Oncol., 23: 42-50, 1996.
21. de Gramont, A., Vignoud, J., Tournigand, C., Louvet, C., Andre, T., Varette, C., Raymond, E., Moreau, S., Le Bail, N., and Krulik, M. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. Eur. J. Cancer, 33: 214-219, 1997.
22. Levi, F., Perpoint, B., Garufi, C., Focan, C., Chollet, P., Depres-Brummer, P., Zidani, R., Brienza, S., Itzhaki, M., Iacobelli, S., et al. Oxaliplatin activity against metastatic colorectal cancer: a Phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur. J. Cancer, 9: 1280-1284, 1993.
23. Becouarn, Y., Ychou, M., Ducreux, M., Borel, C., Bertheault-Cvitkovic, F., Seitz, J. F., Nasca, S., Rougier, P., Nguyen, T. D., Paillot, B., Raoul, J. L., and Fandi, A. Oxaliplatin (I-OHP) as first line chemotherapy in metastatic colorectal cancer (MCRC) patients: preliminary activity/toxicity report. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 229, 1997.
24. Machover, D., Diaz-Rubio, E., de Gramont, A., Schilf, A., Gastiaburu, J. J., Brienza, S., Itzhaki, M., Metzger, G., N'Daw, D., Vignoud, J., Abad, A., Francois, E., Gamelin, E., Marty, M., Sastre, J., Seitz, J. F., and Ychou, M. Two consecutive Phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann. Oncol., 7: 95-98, 1996.
25. Bleiberg, H., Gamelin, E., Francois, E., Andre, T., Extra, J. M., Nole, F., Bensmaine, M. A., Itzhaki, M., Brienza, S., and Cvitkovic, E. Oxaliplatin (1-OHP) synergistic clinical activity with 5-fluorouracil (FU) in FU-resistant colorectal cancer (CRC) patients (pts) is independent of FU +/-folinic acid (FA). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 206, 1996.
26. Von Hoff, D., Sandbach, J., Clark, G., Turner, J., Forseth, B., Piccart, M., Colombo, N., and Muggia, F. Selection of cancer chemotherapy for patient by an in vitro assay versus a clinician. J. Natl. Cancer Inst., 82: 110-116, 1990.
27. Von Hoff, D., Clark, G., Stogdill, B., Sarosdy, M., O'Brien, M., Casper, T., Mattox, D., Page, C., Cruz, A., and Sandbach, J. Prospective clinical trial of human tumor cloning system. Cancer Res., 43: 1926-1931, 1983.
28. Von Hoff, D. Human tumor stem cell assay. Curr. Ther. Hematol. Oncol., 3: 365-367, 1987.
29. Mathe, G., Kidani, Y., Noji, M., Maral, R., Bourut, C., and Chenu, E. Antitumor activity of 1-OHP in mice. Cancer Lett., 27: 135-143, 1985.
30. Tashiro, T., Kawada, Y., Sakurai, Y., and Kidani, Y. Antitumor activity of a new platinum complex oxalato (trans-l-1,2-diaminocyclohexane)platinum(II): new experimental data. Biomed. Pharmacother., 43: 251-260, 1989.
31. Mathe, G., Kidani, Y., Segiguchi, M., Edguchi, M., Fredj, G., Peytavin, G., Misset, J. L., Brienza, S., de Vassal, F., and Chenu, E. Oxalato-platinum or l-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed. Pharmacother., 43: 237-250, 1989.
32. Kidani, Y., Inagaki, K., Saito, R., and Tsukagshi, S. Synthesis and anti-tumor activities of platinum (II) complexes of 1,2-diaminocyclohexane isomers and their related activities. J. Clin. Haematol. Oncol., 7: 197-209, 1977.
33. Bleiberg, H. Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin. Oncol., 23: 42-50, 1996.
34. Caussanel, J. P., Levi, F., Brienza, S., Misset, J. L., Itzhaki, M., Adam, R., Milano, G., Hecquet, B., and Mathe, G. Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J. Natl. Cancer Inst., 82: 1046-1050, 1990.
35. Pendyala, L., Creaven, P. J., Perez, R., Zdanowicz, J. R., and Raghavan, D. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemother. Pharmacol., 36: 271-278, 1995.
36. Aebi, S., Kurdihaidar, B., Gordon, R., Cenni, B., Zheng, H., Fink, D., Christen, R. D., Boland, C. R., Koi, M., and Fishel, R. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res., 5: 3087-3090, 1996.
37. Mello, J. A., Acharya, S., Fishel, R., and Essigann, J. M. The mismatch-repair protein hMSH2 binds selectively to DNA adducts of the anticancer drug cisplatin. Chem. Biol., 3: 579-589, 1996.
38. 4-methylthymine or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA, 93: 6443-6447, 1996.